Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

, REGN

Regeneron

$373.47

-12.58 (-3.26%)

12:30
10/13/16
10/13
12:30
10/13/16
12:30

Ocular deal with Regeneron has favorable terms, says BTIG

BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

  • 13

    Oct

  • 15

    Oct

  • 30

    Oct

  • 04

    Nov

  • 29

    Nov

  • 29

    Mar

OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

TODAY'S FREE FLY STORIES

GRUB

GrubHub

, AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

08:52
09/26/17
09/26
08:52
09/26/17
08:52
Recommendations
GrubHub, Amazon.com analyst commentary  »

Wedbush remains bullish…

GRUB

GrubHub

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

08:50
09/26/17
09/26
08:50
09/26/17
08:50
General news
Treasury 2-year auction outlook: »

Treasury 2-year auction…

W

Wayfair

$71.23

-3.36 (-4.50%)

08:48
09/26/17
09/26
08:48
09/26/17
08:48
Hot Stocks
Wayfair unveils real-time furniture delivery tracking »

Wayfair announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYSZ

MySize

$0.71

-0.0063 (-0.88%)

08:46
09/26/17
09/26
08:46
09/26/17
08:46
Hot Stocks
MySize awarded first patent »

My Size announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$53.23

-0.01 (-0.02%)

, ADDYY

adidas

$113.80

-1.22 (-1.06%)

08:45
09/26/17
09/26
08:45
09/26/17
08:45
Recommendations
Nike, adidas, Under Armour, lululemon analyst commentary  »

Survey respondents more…

NKE

Nike

$53.23

-0.01 (-0.02%)

ADDYY

adidas

$113.80

-1.22 (-1.06%)

UAA

Under Armour

$16.74

0.33 (2.01%)

LULU

lululemon

$57.39

-0.75 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

SN

Sanchez Energy

$4.99

0.38 (8.24%)

, SHLD

Sears

$7.14

0.03 (0.42%)

08:45
09/26/17
09/26
08:45
09/26/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

SN

Sanchez Energy

$4.99

0.38 (8.24%)

SHLD

Sears

$7.14

0.03 (0.42%)

USO

United States Oil Fund

$10.55

0.31 (3.03%)

UCO

Universal Compression

$18.28

1.09 (6.34%)

JUNO

Juno Therapeutics

$42.33

-2.81 (-6.23%)

HIMX

Himax

$9.50

-0.66 (-6.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 08

    Nov

  • 14

    Nov

  • 16

    May

DDAIF

Daimler AG

$78.84

-0.86 (-1.08%)

, TSLA

Tesla

$344.99

-6.1 (-1.74%)

08:44
09/26/17
09/26
08:44
09/26/17
08:44
Periodicals
Daimler responds to Elon Musk tweet on electric vehicles, TechCrunch says »

Daimler (DDAIF) announced…

DDAIF

Daimler AG

$78.84

-0.86 (-1.08%)

TSLA

Tesla

$344.99

-6.1 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

DVCR

Diversicare

$11.10

0.1 (0.91%)

, OHI

Omega Healthcare

$32.45

0.36 (1.12%)

08:43
09/26/17
09/26
08:43
09/26/17
08:43
Hot Stocks
Diversicare, Omega Healthcare agree to terms of new master lease »

Diversicare Healthcare…

DVCR

Diversicare

$11.10

0.1 (0.91%)

OHI

Omega Healthcare

$32.45

0.36 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

08:43
09/26/17
09/26
08:43
09/26/17
08:43
Hot Stocks
Darden says expects impact of Hurricane Irma to be double that of Harvey »

Says Irma impact factored…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMRS

Amyris

$3.21

-0.29 (-8.29%)

08:42
09/26/17
09/26
08:42
09/26/17
08:42
Hot Stocks
Amyris enters second product development, production agreement with Royal DSM »

Amyris announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$66.62

0.58 (0.88%)

08:42
09/26/17
09/26
08:42
09/26/17
08:42
Conference/Events
The Executives' Club of Chicago holds a luncheon meeting »

The Executives' Club…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

08:40
09/26/17
09/26
08:40
09/26/17
08:40
General news
U.S. equities are mostly mildly firmer »

U.S. equities are mostly…

08:40
09/26/17
09/26
08:40
09/26/17
08:40
General news
Breaking General news story  »

Week of 9/23 Redbook to…

DRI

Darden

$83.14

0.26 (0.31%)

08:39
09/26/17
09/26
08:39
09/26/17
08:39
Hot Stocks
Breaking Hot Stocks news story on Darden »

Darden says Hurricane…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

NVDA

Nvidia

08:38
09/26/17
09/26
08:38
09/26/17
08:38
Technical Analysis
Technical View: Nvidia bounces back from prior session losses »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$8.49

0.01 (0.12%)

08:38
09/26/17
09/26
08:38
09/26/17
08:38
Recommendations
Veracyte analyst commentary  »

Veracyte visibility…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

08:36
09/26/17
09/26
08:36
09/26/17
08:36
Hot Stocks
Darden says all businesses 'remain strong' »

Says to-go sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

TEUM

Pareteum

$1.06

0.01 (0.95%)

08:35
09/26/17
09/26
08:35
09/26/17
08:35
Hot Stocks
Breaking Hot Stocks news story on Pareteum »

Pareteum Corp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVEE

NV5 Global

$53.85

2.15 (4.16%)

08:34
09/26/17
09/26
08:34
09/26/17
08:34
Hot Stocks
NV5 Global awarded $14M program management contract by Merced County »

NV5 Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CSBR

Champions Oncology

$3.66

-0.09 (-2.40%)

08:33
09/26/17
09/26
08:33
09/26/17
08:33
Hot Stocks
Champions Oncology awarded $2M from National Cancer Institute »

Champions Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.96

0.03 (1.55%)

, UNIT

Uniti Group

$17.36

0.85 (5.15%)

08:33
09/26/17
09/26
08:33
09/26/17
08:33
Hot Stocks
Windstream says allegations in purported notice of default 'without merit' »

In a regulatory filing…

WIN

Windstream

$1.96

0.03 (1.55%)

UNIT

Uniti Group

$17.36

0.85 (5.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

OSIS

OSI Systems

$85.81

-1.08 (-1.24%)

08:32
09/26/17
09/26
08:32
09/26/17
08:32
Hot Stocks
OSI Systems receives $16M in orders for ETD systems »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Oct

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

08:32
09/26/17
09/26
08:32
09/26/17
08:32
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant says Mindset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GILD

Gilead

$83.61

0.34 (0.41%)

, KITE

Kite Pharma

$179.31

0.01 (0.01%)

08:31
09/26/17
09/26
08:31
09/26/17
08:31
Hot Stocks
Gilead, Kite Pharma announce expiration of HSR waiting period »

Gilead Sciences (GILD)…

GILD

Gilead

$83.61

0.34 (0.41%)

KITE

Kite Pharma

$179.31

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 12

    Feb

08:31
09/26/17
09/26
08:31
09/26/17
08:31
Conference/Events
Federal Reserve Bank of Atlanta President speaks on the economic outlook »

Atlanta Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.